pharmaphorum

APRIL 20, 2022

A meta-analysis of published studies looking at web- app- or telehealth-based therapy for osteoarthritis has concluded that they outperform standard approaches to care. The study – published in the journal Osteoarthritis and Cartilage – focused on patients with osteoarthritis of the hip or knee, and compared the digitally-delivered exercises to standard approaches such as in-person physiotherapy, other forms of care, waitlisting and patient education.

103

103

Outsourcing Pharma

APRIL 20, 2022

The two-day Oracle Health Sciences Connect will gather an array of research experts to discuss how to make the most of emerging technologies and practices.

111

111

pharmaphorum

APRIL 20, 2022

Teva’s long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company’s long-acting formulation of schizophrenia drug risperidone. The US regulator issued a complete response letter (CRL) for the MedinCell-partnered drug, and the companies haven’t been forthcoming on the reasons behind the rejection, saying merely that they would work with the FDA to try to get the programme back on track.

FDA 98

FDA 98

Outsourcing Pharma

APRIL 20, 2022

An expert from the health tech company explains how AI, natural language processing, and other tools can improve pharmaceutical product safety reporting.

91

91

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 20, 2022

Gilead has won a crucial court order in a wide-ranging lawsuit against a network of clinics, prescribers, medical labs and pharmacies in Florida that it claims have been making fraudulent reimbursement claims for HIV medicines. The suit focuses on alleged abuse of Gilead’s Advancing Access programme, a scheme set up in 2004 to provide HIV therapies at no charge to people who lack heath insurance and would be unable to get access to the drugs.

Insurance 69

Insurance 69

PharmD Live

APRIL 20, 2022

By Jisha Thomas, PharmD. Introduction. Obesity rates are at an all-time high at 42.4%, according to the latest CDC records from 2017 to 2018. This number has increased dramatically from 30.5% according to the records ranging from 1999 to 2000. 1 Obesity increases the risk for many health problems, such as type 2 diabetes, high blood pressure, heart disease, stroke, joint disorders, liver disease, gallstones, some types of cancer, and sleep apnea among other conditions. 2 More recently, obesity h

Hospitals 52

Hospitals FDA 52

indispensable health

APRIL 20, 2022

Indispensable Health’s pharmacy staffing department, Staff Rx , discussed the work experiences of our talented staffing pharmacists and pharmacy technicians in order to provide others with advice who may be considering working for a staffing agency. What’s different about working with a staffing agency as a pharmacist, pharmacy technician, or any interim pharmacy professional?

Communication 52

Communication Hospitals 52

Roots Analysis

APRIL 20, 2022

On an average, around 50 drugs are approved by the US Food and Drug Administration (US FDA) annually. Further, studies indicate that more than 100,000 tons of pharmaceutical products are consumed globally per year. In addition, over the next five years, the global pharmaceutical market is projected to grow at a CAGR of 4.7%, with global drug sales anticipated to raise revenues worth USD 1.5 trillion in 2023.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Labelling 52

pharmaphorum

APRIL 20, 2022

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in the biotech sector. The $10.50-per-share deal values CheckMate at around $250 million, and revolves around the toll-like receptor-9 (TKR9) agonist, which is in clinical testing in combination with other drugs for melanoma and non-melanoma skin cancers, as well as head and neck cancer.

Immunization 52

Immunization FDA 52

Outsourcing Pharma

APRIL 20, 2022

The maker of active pharmaceutical ingredients for inhaled treatments is investing â9m ($9.8m USD) to expand its manufacturing plant in Barcelona, Spain.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

APRIL 20, 2022

SMi Group Reports: The leading Pain Therapeutics Conference will take place for its 22nd consecutive year on 4th and 5th May 2022 in London, UK to explore novel compounds and treatments for pain: opioids and the alternatives. SMi Group is pleased to announce the 22nd Annual Pain Therapeutics Conference taking place in London, UK on 4th and 5th May 2022.

Compounding 52

Compounding 52

Med Ed 101

APRIL 20, 2022

Throughout my career, I have had various clinicians develop trends in the NSAID that they prefer to use. Why do we choose ibuprofen versus diclofenac versus piroxicam? In this post, I will be ranking NSAIDs according to their GI risk based upon the literature we have. This may help explain why we choose one NSAID […]. The post Ranking NSAIDs According To GI Risk appeared first on Med Ed 101.

45

45

pharmaphorum

APRIL 20, 2022

Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to offer improved protection. The booster shot – called mRNA-1273.211 – offered better and longer-lasting protection compared to the original SpikeVax shot against all SARS-CoV-2 variants, including the prevailing Omicron strain.

Vaccines 52

Vaccines Immunization 52

Pharma Times

APRIL 20, 2022

‘The Eyes Have It’ partnership will highlight the importance of eye health

53

53

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

APRIL 20, 2022

Acute Respiratory Distress Syndrome (ARDS) is a growing and concerning unmet medical need with no effective therapeutic, and a serious medical burden in a world with or without COVID-19. Bringing industry together to consolidate the last 18 months of clinical and translational data; the 2nd ARDS Drug Development Summit is the only translational conference for drug developers to leverage the large homogeneous populations of COVID ARDS, and finally advance clinically successful therapeutics past h

52

52

Pharma Times

APRIL 20, 2022

Company at the forefront of developing personalised treatments against invasive cancer has raised 15m euros to conduct clinical trials

42

42

pharmaphorum

APRIL 20, 2022

The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into the clinic, what therapeutic areas could be set to benefit? Ben Hargreaves takes a look at why oncology could be one of the major beneficiaries of a growing pipeline of CRISPR therapeutics. The breakthrough for CRISPR technology happened only a decade ago.

Chemotherapy 52

Chemotherapy Immunization 52